DYDRORITE-30SR
MRP: 1,30,000
Packaging: 10 x 10
Pack Type: tablet
Composition:
Dydrogesterone (30mg SR)
Indication:
For Progesterone Deficiencies: Regulation of menstrual cycle, Threatened abortion, Endometriosis, Pre-menstrual syndrome, Dysmenorrhoea, Dysfunctional uterine bleeding, Secondary amenorrhoea
Description:
Dydrogesterone 30 mg (Sustained Release) is a synthetic progestogen used primarily in the treatment of menstrual disorders, hormonal imbalance, and progesterone deficiency conditions. This SR (Sustained Release) formulation ensures stable plasma levels, offering prolonged action and improved compliance with once-daily dosing.
It mimics natural progesterone and is prescribed in conditions such as secondary amenorrhea, dysmenorrhea, endometriosis, irregular cycles, threatened or habitual miscarriage, and assisted reproductive therapies (ART). Unlike older progestins, dydrogesterone does not have androgenic, estrogenic, or glucocorticoid activity, making it well tolerated.
Tags:
- Effective treatment for menstrual irregularities, dysmenorrhea, and secondary amenorrhea
- Supports endometrial transformation in infertility and IVF
- Prevents threatened and recurrent miscarriage due to luteal insufficiency
- Provides hormonal balance without androgenic or estrogenic side effects
- Convenient once-daily SR formulation ensures sustained progesterone levels
- Safe for use in pregnancy and hormone replacement therapies
Usage Information
Dosage
Usual dose: 1 tablet (30 mg SR) once daily or as directed by a physician Timing and duration depend on the indication (e.g., menstrual cycle phase, fertility support) Should be taken at the same time every day with or without food
Side Effects
Common: Headache, nausea, breast tenderness, mild fatigue Rare: Skin rash, mood changes, abdominal discomfort Generally well tolerated due to selective progesterone activity
Contraindications
Known hypersensitivity to dydrogesterone or excipients Undiagnosed vaginal bleeding Severe hepatic impairment Known or suspected hormone-sensitive cancers (e.g., breast cancer) Use in combination with estrogens requires caution and medical supervision